#Ireland #Dublin #GSK #Theravance Biopharma #Trelegy Ellipta

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta

Theravance Biopharma, Inc. has made a significant move by selling its remaining royalty interest in the Trelegy Ellipta to GSK for a staggering $225 million. This definitive agreement is not just a financial transaction; it's a strategic step aimed at maximizing shareholder value, which has been a priority for the company's board of directors.

Details of the Transaction

The agreement facilitates a one-time cash payment of $225 million, while Theravance retains the rights to potentially earn up to $150 million in additional milestone payments based on Trelegy's net sales during 2025 and 2026. To achieve these milestones, minimal growth in sales over 2024 actuals is required, making these targets relatively attainable.

This latest royalty transaction adds to the already substantial amount of $1.1 billion that Theravance received from Royalty Pharma in 2022, which was also related to Trelegy royalties. The total potential lifetime value from Theravance’s efforts to monetize Trelegy now stands at an extraordinary $1.525 billion.

CEO’s Perspective

Rick E Winningham, CEO of Theravance Biopharma, expressed confidence in the sustained success of Trelegy, stating that this agreement translates their long-standing belief in the product's value into immediate economic benefits for shareholders. The initial sale of Trelegy royalty interests indeed bolstered the company's balance sheet, enabling them to return substantial capital back to shareholders.

Winningham indicated that the decision to retain future royalties during the initial sale was fueled by a commitment to maximizing value, reiterating the long-term potential of Trelegy in the market. He further mentioned that the current agreement is a validation of their strategy and reflects ongoing commitment to driving growth in other areas like the YUPELRI and ampreloxetine products, which are in various stages of development.

Historical Context

Theravance’s economic interest in Trelegy emanates from a collaboration agreement established in 2002 with GSK, under which Theravance’s precursor pooled its long-acting beta agonist (LABA) assets with GSK. This partnership gave rise to several combination products, including Trelegy, thus generating royalties for Theravance.

In 2022, Royalty Pharma purchased Theravance’s core royalty rights for a hefty upfront payment, alongside additional milestones, while allowing the company to maintain rights to the majority of royalties from Trelegy sales beyond certain dates. This strategic sale marks a substantial turnaround in Theravance’s approach to monetizing its assets, reinforcing its fiscal health.

Looking Ahead

With this agreement finalized, Theravance Biopharma is poised to monitor the implications of Trelegy sales closely. Their guidance for 2025 remains steadied, further signaling the well-calibrated nature of their strategic reviews as they persist in evaluating all available avenues to enhance shareholder value.

Experts from Lazard acted as financial advisors, while Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel to Theravance throughout this deal.

Overall, this transaction exemplifies Theravance's commitment to strategic growth and shareholder engagement while fostering innovation in its pharmaceutical portfolio. For ongoing updates, investors and interested parties are encouraged to visit Theravance’s official website or stay attuned to future press releases that outline additional developments.

Conclusion

Theravance Biopharma's recent transaction with GSK serves not only as a substantial influx of cash but also marks a pivotal moment in the company’s strategy to maximize shareholder returns and focus on core growth initiatives. As they continue to develop and bring impactful medicines to the market, stakeholders remain invested in their journey moving forward.